Stock ANIP ANI PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings ANI Pharmaceuticals, Inc.

Equities

ANIP

US00182C1036

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
64.9 USD +2.27% Intraday chart for ANI Pharmaceuticals, Inc. +5.84% +17.70%
May. 21 Ani Pharmaceuticals Insider Sold Shares Worth $794,568, According to a Recent SEC Filing MT
May. 20 ANI Pharmaceuticals Launches Kionex Suspension MT

Summary

  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The company's profit outlook over the next few years is a strong asset.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • With an expected P/E ratio at 41.43 and 27.04 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ANI PHARMACEUTICALS, INC. Stock ANI Pharmaceuticals, Inc.
+17.70% 1.26B
C-
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
B+
NOVARTIS AG Stock Novartis AG
+9.78% 210B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
A+
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ANIP Stock
  4. Ratings ANI Pharmaceuticals, Inc.